Lostad HCT 100/25mg Film-coated tablet

देश: मलेशिया

भाषा: अंग्रेज़ी

स्रोत: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

सक्रिय संघटक:

LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE

थमां उपलब्ध:

STADPHARM SDN. BHD.

INN (इंटरनेशनल नाम):

LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE

पैकेज में यूनिट:

30tablet Tablets

द्वारा बनाया गया:

STELLAPHARM J.V. Co., LTD. - BRANCH 1

सूचना पत्रक

_Consumer Medication Information Leaflet (RiMUP)_
LOSTAD HCT FILM COATED TABLETS
One tablet of LOSTAD HCT 50/12.5 contains 50 mg of Losartan potassium
and 12.5 mg of Hydrochlorothiazide
One tablet of LOSTAD HCT 100/25 contains 100 mg of Losartan potassium
and 25 mg of Hydrochlorothiazide
WHAT IS IN THIS LEAFLET
1.
What LOSTAD HCT is used for
2.
How LOSTAD HCT works
3.
Before you use LOSTAD HCT
4.
How to use LOSTAD HCT
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of LOSTAD HCT
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
11.
Serial Number
WHAT LOSTAD HCT IS USED FOR
LOSTAD HCT is used for the treatment
of high blood pressure. This drug is not
used for initial therapy of high blood
pressure,
except
when
it
is
severe
enough that the value of a achieving
prompt blood pressure control exceeds
the risk of initiating therapy in these
patients. LOSTAD HCT is used to reduce
the risk of stroke (a sudden attack of
weakness
affecting
one
side
of
the
body)
in
patients
with
high
blood
pressure
and
left
ventricular
hypertrophy
(the
thickening
of
the
muscle of the left ventricle of the heart),
but there is evidence that this benefit
does not apply to Black patients.
HOW LOSTAD HCT WORKS
LOSTAD
HCT
is
a
combination
of
Losartan
potassium
and
Hydrochlorothiazide.
Losartan
is
an
angiotensin
II
receptor
antagonists.
Losartan
keeps
blood
vessels
from
narrowing, which lowers blood pressure
and
improves
blood
flow.
Hydrochlorothiazide
is
a
thiazide
diuretic (water pill) that helps prevent
your
body
from
absorbing
too
much
salt, which can cause fluid retention.
BEFORE YOU USE LOSTAD HCT
_WHEN YOU MUST NOT USE IT _
-
If you are allergic (hypersensitive)
to any component of this product.
-
If
you
are
allergic
to
other
sulfonamide-derived drugs.
-
If you are unable to urinate.
-
If you are pregnant.
_BEFORE YOU START TO USE IT _
_If any of the situations mentioned below _
_apply to you, you should tell your doctor _
_before taking this drug: _
-
If
you
have
renal
artery
ste

उत्पाद विशेषताएं

LOSTAD HCT 100/25
COMPOSITION
Active ingredient: One film-coated tablet contains 100 mg of Losartan
potassium and 25 mg of Hydrochlorothiazide.
PHARMACODYNAMICS
Losartan and its principal active metabolite block the vasoconstrictor
and aldosterone-secreting effects of angiotensin II by selectively
blocking the binding of angiotensin II
to the AT
1
receptor found in many tissues, (e.g., vascular smooth muscle, adrenal
gland). The active metabolite is 10 to 40 times more potent by weight
than losartan and
appears to be a reversible, non-competitive inhibitor of the AT
1
receptor. Neither losartan nor its active metabolite inhibits ACE
(kininase II, the enzyme that converts
angiotensin I to angiotensin II and degrades bradykinin); nor do they
bind to or block other hormone receptors or ion channels known to be
important in cardiovascular
regulation.
Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal
tubular mechanisms of electrolyte reabsorption, directly increasing
excretion of sodium and chloride in
approximately equivalent amounts. Indirectly, the diuretic action of
hydrochlorothiazide reduces plasma volume, with aldosterone secretion,
increases in urinary potassium.
The renin - aldosterone link is mediated by angiotensin II, so
co-administration of an angiotensin II receptor antagonist tends to
reverse the potassium loss associated with
these diuretics. The mechanism of the antihypertensive effect of
thiazides is unknown.
Non-melanoma skin cancer: Based on available data from epidemiological
studies, cumulative dose-dependent association between HCTZ and NMSC
has been observed.
One study included a population comprised of 71,533 cases of BCC and
of 8,629 cases of SCC matched to 1,430,833 and 172,462 population
controls, respectively. High
HCTZ use (250,000 mg cumulative) was associated with an adjusted OR of
1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% Cl: 3.68-4.31) for SCC.
A clear cumulative
dose response relationship was observed for both BCC and SCC. Another
study showed a possible ass